Chemogenetic	B:C1148560
stimulation	I:C1148560
of	O
striatal	O
projection	I:C0027882
neurons	I:C0027882
modulates	O
responses	O
to	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
therapy	O
.	O

Chemogenetic	O
stimulation	I:C1148560
of	O
striatal	B:C0027882
projection	I:C0027882
neurons	I:C0027882
modulates	O
responses	O
to	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
therapy	O
.	O

Chemogenetic	O
stimulation	I:C1148560
of	O
striatal	O
projection	I:C0027882
neurons	I:C0027882
modulates	O
responses	O
to	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
therapy	O
.	O

Chemogenetic	O
stimulation	I:C1148560
of	O
striatal	O
projection	I:C0027882
neurons	I:C0027882
modulates	O
responses	O
to	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
therapy	B:C0087111
.	O

Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
patients	O
experience	O
loss	O
of	I:C1864672
normal	I:C1864672
motor	I:C1864672
function	I:C1864672
(	O
hypokinesia	O
)	O
,	O
but	O
can	O
develop	O
uncontrollable	O
movements	I:C0013384
known	O
as	O
dyskinesia	O
upon	O
treatment	O
with	O
L	O
-	I:C0023570
DOPA	I:C0023570
.	O

Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
)	O
patients	O
experience	O
loss	O
of	I:C1864672
normal	I:C1864672
motor	I:C1864672
function	I:C1864672
(	O
hypokinesia	O
)	O
,	O
but	O
can	O
develop	O
uncontrollable	O
movements	I:C0013384
known	O
as	O
dyskinesia	O
upon	O
treatment	O
with	O
L	O
-	I:C0023570
DOPA	I:C0023570
.	O

Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
patients	O
experience	B:C0596545
loss	O
of	I:C1864672
normal	I:C1864672
motor	I:C1864672
function	I:C1864672
(	O
hypokinesia	O
)	O
,	O
but	O
can	O
develop	O
uncontrollable	O
movements	I:C0013384
known	O
as	O
dyskinesia	O
upon	O
treatment	O
with	O
L	O
-	I:C0023570
DOPA	I:C0023570
.	O

Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
patients	O
experience	O
loss	B:C1864672
of	I:C1864672
normal	I:C1864672
motor	I:C1864672
function	I:C1864672
(	O
hypokinesia	O
)	O
,	O
but	O
can	O
develop	O
uncontrollable	O
movements	I:C0013384
known	O
as	O
dyskinesia	O
upon	O
treatment	O
with	O
L	O
-	I:C0023570
DOPA	I:C0023570
.	O

Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
patients	O
experience	O
loss	O
of	I:C1864672
normal	I:C1864672
motor	I:C1864672
function	I:C1864672
(	O
hypokinesia	B:C0086439
)	O
,	O
but	O
can	O
develop	O
uncontrollable	O
movements	I:C0013384
known	O
as	O
dyskinesia	O
upon	O
treatment	O
with	O
L	O
-	I:C0023570
DOPA	I:C0023570
.	O

Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
patients	O
experience	O
loss	O
of	I:C1864672
normal	I:C1864672
motor	I:C1864672
function	I:C1864672
(	O
hypokinesia	O
)	O
,	O
but	O
can	O
develop	O
uncontrollable	B:C0013384
movements	I:C0013384
known	O
as	O
dyskinesia	O
upon	O
treatment	O
with	O
L	O
-	I:C0023570
DOPA	I:C0023570
.	O

Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
patients	O
experience	O
loss	O
of	I:C1864672
normal	I:C1864672
motor	I:C1864672
function	I:C1864672
(	O
hypokinesia	O
)	O
,	O
but	O
can	O
develop	O
uncontrollable	O
movements	I:C0013384
known	O
as	O
dyskinesia	B:C0013384
upon	O
treatment	O
with	O
L	O
-	I:C0023570
DOPA	I:C0023570
.	O

Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
patients	O
experience	O
loss	O
of	I:C1864672
normal	I:C1864672
motor	I:C1864672
function	I:C1864672
(	O
hypokinesia	O
)	O
,	O
but	O
can	O
develop	O
uncontrollable	O
movements	I:C0013384
known	O
as	O
dyskinesia	O
upon	O
treatment	B:C0087111
with	O
L	O
-	I:C0023570
DOPA	I:C0023570
.	O

Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
patients	O
experience	O
loss	O
of	I:C1864672
normal	I:C1864672
motor	I:C1864672
function	I:C1864672
(	O
hypokinesia	O
)	O
,	O
but	O
can	O
develop	O
uncontrollable	O
movements	I:C0013384
known	O
as	O
dyskinesia	O
upon	O
treatment	O
with	O
L	B:C0023570
-	I:C0023570
DOPA	I:C0023570
.	O

Poverty	O
or	O
excess	O
of	O
movement	B:C0026649
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
has	O
been	O
attributed	O
to	O
overactivity	O
of	O
striatal	O
projection	I:C0027882
neurons	I:C0027882
forming	O
either	O
the	O
indirect	O
(	O
iSPNs	O
)	O
or	O
the	O
direct	O
(	O
dSPNs	O
)	O
pathway	O
,	O
respectively	O
.	O

Poverty	O
or	O
excess	O
of	O
movement	O
in	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
has	O
been	O
attributed	O
to	O
overactivity	O
of	O
striatal	O
projection	I:C0027882
neurons	I:C0027882
forming	O
either	O
the	O
indirect	O
(	O
iSPNs	O
)	O
or	O
the	O
direct	O
(	O
dSPNs	O
)	O
pathway	O
,	O
respectively	O
.	O

Poverty	O
or	O
excess	O
of	O
movement	O
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
has	O
been	O
attributed	O
to	O
overactivity	B:C1536696
of	O
striatal	O
projection	I:C0027882
neurons	I:C0027882
forming	O
either	O
the	O
indirect	O
(	O
iSPNs	O
)	O
or	O
the	O
direct	O
(	O
dSPNs	O
)	O
pathway	O
,	O
respectively	O
.	O

Poverty	O
or	O
excess	O
of	O
movement	O
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
has	O
been	O
attributed	O
to	O
overactivity	O
of	O
striatal	B:C0027882
projection	I:C0027882
neurons	I:C0027882
forming	O
either	O
the	O
indirect	O
(	O
iSPNs	O
)	O
or	O
the	O
direct	O
(	O
dSPNs	O
)	O
pathway	O
,	O
respectively	O
.	O

Poverty	O
or	O
excess	O
of	O
movement	O
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
has	O
been	O
attributed	O
to	O
overactivity	O
of	O
striatal	O
projection	I:C0027882
neurons	I:C0027882
forming	O
either	O
the	O
indirect	O
(	O
iSPNs	B:C0027882
)	O
or	O
the	O
direct	O
(	O
dSPNs	O
)	O
pathway	O
,	O
respectively	O
.	O

Poverty	O
or	O
excess	O
of	O
movement	O
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
has	O
been	O
attributed	O
to	O
overactivity	O
of	O
striatal	O
projection	I:C0027882
neurons	I:C0027882
forming	O
either	O
the	O
indirect	O
(	O
iSPNs	O
)	O
or	O
the	O
direct	O
(	O
dSPNs	B:C0027882
)	O
pathway	O
,	O
respectively	O
.	O

Poverty	O
or	O
excess	O
of	O
movement	O
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
has	O
been	O
attributed	O
to	O
overactivity	O
of	O
striatal	O
projection	I:C0027882
neurons	I:C0027882
forming	O
either	O
the	O
indirect	O
(	O
iSPNs	O
)	O
or	O
the	O
direct	O
(	O
dSPNs	O
)	O
pathway	B:C0027792
,	O
respectively	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
two	O
pathways	B:C0027792
'	O
contribution	O
to	O
different	O
motor	O
features	O
using	O
SPN	O
type	I:C1148560
-	I:C1148560
specific	I:C1148560
chemogenetic	I:C1148560
stimulation	I:C1148560
in	O
rodent	O
models	I:C1519106
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
)	O
and	O
L	O
-	I:C3552620
DOPA	I:C3552620
-	I:C3552620
induced	I:C3552620
dyskinesia	I:C3552620
(	O
LID	O
mice	O
)	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
two	O
pathways	O
'	O
contribution	O
to	O
different	O
motor	B:C0026609
features	O
using	O
SPN	O
type	I:C1148560
-	I:C1148560
specific	I:C1148560
chemogenetic	I:C1148560
stimulation	I:C1148560
in	O
rodent	O
models	I:C1519106
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
)	O
and	O
L	O
-	I:C3552620
DOPA	I:C3552620
-	I:C3552620
induced	I:C3552620
dyskinesia	I:C3552620
(	O
LID	O
mice	O
)	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
two	O
pathways	O
'	O
contribution	O
to	O
different	O
motor	O
features	O
using	O
SPN	B:C1148560
type	I:C1148560
-	I:C1148560
specific	I:C1148560
chemogenetic	I:C1148560
stimulation	I:C1148560
in	O
rodent	O
models	I:C1519106
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
)	O
and	O
L	O
-	I:C3552620
DOPA	I:C3552620
-	I:C3552620
induced	I:C3552620
dyskinesia	I:C3552620
(	O
LID	O
mice	O
)	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
two	O
pathways	O
'	O
contribution	O
to	O
different	O
motor	O
features	O
using	O
SPN	O
type	I:C1148560
-	I:C1148560
specific	I:C1148560
chemogenetic	I:C1148560
stimulation	I:C1148560
in	O
rodent	B:C1519106
models	I:C1519106
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
)	O
and	O
L	O
-	I:C3552620
DOPA	I:C3552620
-	I:C3552620
induced	I:C3552620
dyskinesia	I:C3552620
(	O
LID	O
mice	O
)	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
two	O
pathways	O
'	O
contribution	O
to	O
different	O
motor	O
features	O
using	O
SPN	O
type	I:C1148560
-	I:C1148560
specific	I:C1148560
chemogenetic	I:C1148560
stimulation	I:C1148560
in	O
rodent	O
models	I:C1519106
of	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
)	O
and	O
L	O
-	I:C3552620
DOPA	I:C3552620
-	I:C3552620
induced	I:C3552620
dyskinesia	I:C3552620
(	O
LID	O
mice	O
)	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
two	O
pathways	O
'	O
contribution	O
to	O
different	O
motor	O
features	O
using	O
SPN	O
type	I:C1148560
-	I:C1148560
specific	I:C1148560
chemogenetic	I:C1148560
stimulation	I:C1148560
in	O
rodent	O
models	I:C1519106
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
mice	O
)	O
and	O
L	O
-	I:C3552620
DOPA	I:C3552620
-	I:C3552620
induced	I:C3552620
dyskinesia	I:C3552620
(	O
LID	O
mice	O
)	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
two	O
pathways	O
'	O
contribution	O
to	O
different	O
motor	O
features	O
using	O
SPN	O
type	I:C1148560
-	I:C1148560
specific	I:C1148560
chemogenetic	I:C1148560
stimulation	I:C1148560
in	O
rodent	O
models	I:C1519106
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	B:C0025929
)	O
and	O
L	O
-	I:C3552620
DOPA	I:C3552620
-	I:C3552620
induced	I:C3552620
dyskinesia	I:C3552620
(	O
LID	O
mice	O
)	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
two	O
pathways	O
'	O
contribution	O
to	O
different	O
motor	O
features	O
using	O
SPN	O
type	I:C1148560
-	I:C1148560
specific	I:C1148560
chemogenetic	I:C1148560
stimulation	I:C1148560
in	O
rodent	O
models	I:C1519106
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
)	O
and	O
L	B:C3552620
-	I:C3552620
DOPA	I:C3552620
-	I:C3552620
induced	I:C3552620
dyskinesia	I:C3552620
(	O
LID	O
mice	O
)	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
two	O
pathways	O
'	O
contribution	O
to	O
different	O
motor	O
features	O
using	O
SPN	O
type	I:C1148560
-	I:C1148560
specific	I:C1148560
chemogenetic	I:C1148560
stimulation	I:C1148560
in	O
rodent	O
models	I:C1519106
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
)	O
and	O
L	O
-	I:C3552620
DOPA	I:C3552620
-	I:C3552620
induced	I:C3552620
dyskinesia	I:C3552620
(	O
LID	B:C3552620
mice	O
)	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
two	O
pathways	O
'	O
contribution	O
to	O
different	O
motor	O
features	O
using	O
SPN	O
type	I:C1148560
-	I:C1148560
specific	I:C1148560
chemogenetic	I:C1148560
stimulation	I:C1148560
in	O
rodent	O
models	I:C1519106
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
)	O
and	O
L	O
-	I:C3552620
DOPA	I:C3552620
-	I:C3552620
induced	I:C3552620
dyskinesia	I:C3552620
(	O
LID	O
mice	B:C0025929
)	O
.	O

Using	O
the	O
activatory	B:C0289799
Gq	I:C0289799
-	I:C0289799
coupled	I:C0289799
human	I:C0289799
M3	I:C0289799
muscarinic	I:C0289799
receptor	I:C0289799
(	O
hM3Dq	O
)	O
,	O
we	O
found	O
that	O
chemogenetic	O
stimulation	I:C1148560
of	O
dSPNs	O
mimicked	O
,	O
while	O
stimulation	O
of	O
iSPNs	O
abolished	O
the	O
therapeutic	O
action	I:C2712171
of	O
L	O
-	I:C0023570
DOPA	I:C0023570
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
.	O

Using	O
the	O
activatory	O
Gq	I:C0289799
-	I:C0289799
coupled	I:C0289799
human	I:C0289799
M3	I:C0289799
muscarinic	I:C0289799
receptor	I:C0289799
(	O
hM3Dq	B:C0289799
)	O
,	O
we	O
found	O
that	O
chemogenetic	O
stimulation	I:C1148560
of	O
dSPNs	O
mimicked	O
,	O
while	O
stimulation	O
of	O
iSPNs	O
abolished	O
the	O
therapeutic	O
action	I:C2712171
of	O
L	O
-	I:C0023570
DOPA	I:C0023570
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
.	O

Using	O
the	O
activatory	O
Gq	I:C0289799
-	I:C0289799
coupled	I:C0289799
human	I:C0289799
M3	I:C0289799
muscarinic	I:C0289799
receptor	I:C0289799
(	O
hM3Dq	O
)	O
,	O
we	O
found	O
that	O
chemogenetic	B:C1148560
stimulation	I:C1148560
of	O
dSPNs	O
mimicked	O
,	O
while	O
stimulation	O
of	O
iSPNs	O
abolished	O
the	O
therapeutic	O
action	I:C2712171
of	O
L	O
-	I:C0023570
DOPA	I:C0023570
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
.	O

Using	O
the	O
activatory	O
Gq	I:C0289799
-	I:C0289799
coupled	I:C0289799
human	I:C0289799
M3	I:C0289799
muscarinic	I:C0289799
receptor	I:C0289799
(	O
hM3Dq	O
)	O
,	O
we	O
found	O
that	O
chemogenetic	O
stimulation	I:C1148560
of	O
dSPNs	B:C0027882
mimicked	O
,	O
while	O
stimulation	O
of	O
iSPNs	O
abolished	O
the	O
therapeutic	O
action	I:C2712171
of	O
L	O
-	I:C0023570
DOPA	I:C0023570
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
.	O

Using	O
the	O
activatory	O
Gq	I:C0289799
-	I:C0289799
coupled	I:C0289799
human	I:C0289799
M3	I:C0289799
muscarinic	I:C0289799
receptor	I:C0289799
(	O
hM3Dq	O
)	O
,	O
we	O
found	O
that	O
chemogenetic	O
stimulation	I:C1148560
of	O
dSPNs	O
mimicked	O
,	O
while	O
stimulation	B:C1148560
of	O
iSPNs	O
abolished	O
the	O
therapeutic	O
action	I:C2712171
of	O
L	O
-	I:C0023570
DOPA	I:C0023570
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
.	O

Using	O
the	O
activatory	O
Gq	I:C0289799
-	I:C0289799
coupled	I:C0289799
human	I:C0289799
M3	I:C0289799
muscarinic	I:C0289799
receptor	I:C0289799
(	O
hM3Dq	O
)	O
,	O
we	O
found	O
that	O
chemogenetic	O
stimulation	I:C1148560
of	O
dSPNs	O
mimicked	O
,	O
while	O
stimulation	O
of	O
iSPNs	B:C0027882
abolished	O
the	O
therapeutic	O
action	I:C2712171
of	O
L	O
-	I:C0023570
DOPA	I:C0023570
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
.	O

Using	O
the	O
activatory	O
Gq	I:C0289799
-	I:C0289799
coupled	I:C0289799
human	I:C0289799
M3	I:C0289799
muscarinic	I:C0289799
receptor	I:C0289799
(	O
hM3Dq	O
)	O
,	O
we	O
found	O
that	O
chemogenetic	O
stimulation	I:C1148560
of	O
dSPNs	O
mimicked	O
,	O
while	O
stimulation	O
of	O
iSPNs	O
abolished	O
the	O
therapeutic	B:C2712171
action	I:C2712171
of	O
L	O
-	I:C0023570
DOPA	I:C0023570
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
.	O

Using	O
the	O
activatory	O
Gq	I:C0289799
-	I:C0289799
coupled	I:C0289799
human	I:C0289799
M3	I:C0289799
muscarinic	I:C0289799
receptor	I:C0289799
(	O
hM3Dq	O
)	O
,	O
we	O
found	O
that	O
chemogenetic	O
stimulation	I:C1148560
of	O
dSPNs	O
mimicked	O
,	O
while	O
stimulation	O
of	O
iSPNs	O
abolished	O
the	O
therapeutic	O
action	I:C2712171
of	O
L	B:C0023570
-	I:C0023570
DOPA	I:C0023570
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
.	O

Using	O
the	O
activatory	O
Gq	I:C0289799
-	I:C0289799
coupled	I:C0289799
human	I:C0289799
M3	I:C0289799
muscarinic	I:C0289799
receptor	I:C0289799
(	O
hM3Dq	O
)	O
,	O
we	O
found	O
that	O
chemogenetic	O
stimulation	I:C1148560
of	O
dSPNs	O
mimicked	O
,	O
while	O
stimulation	O
of	O
iSPNs	O
abolished	O
the	O
therapeutic	O
action	I:C2712171
of	O
L	O
-	I:C0023570
DOPA	I:C0023570
in	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
mice	O
.	O

Using	O
the	O
activatory	O
Gq	I:C0289799
-	I:C0289799
coupled	I:C0289799
human	I:C0289799
M3	I:C0289799
muscarinic	I:C0289799
receptor	I:C0289799
(	O
hM3Dq	O
)	O
,	O
we	O
found	O
that	O
chemogenetic	O
stimulation	I:C1148560
of	O
dSPNs	O
mimicked	O
,	O
while	O
stimulation	O
of	O
iSPNs	O
abolished	O
the	O
therapeutic	O
action	I:C2712171
of	O
L	O
-	I:C0023570
DOPA	I:C0023570
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	B:C0025929
.	O

In	O
LID	B:C3552620
mice	O
,	O
hM3Dq	O
stimulation	O
of	O
dSPNs	O
exacerbated	O
dyskinetic	O
responses	O
to	O
L	O
-	I:C0023570
DOPA	I:C0023570
,	O
while	O
stimulation	O
of	O
iSPNs	O
inhibited	O
these	O
responses	O
.	O

In	O
LID	O
mice	B:C0025929
,	O
hM3Dq	O
stimulation	O
of	O
dSPNs	O
exacerbated	O
dyskinetic	O
responses	O
to	O
L	O
-	I:C0023570
DOPA	I:C0023570
,	O
while	O
stimulation	O
of	O
iSPNs	O
inhibited	O
these	O
responses	O
.	O

In	O
LID	O
mice	O
,	O
hM3Dq	B:C0289799
stimulation	O
of	O
dSPNs	O
exacerbated	O
dyskinetic	O
responses	O
to	O
L	O
-	I:C0023570
DOPA	I:C0023570
,	O
while	O
stimulation	O
of	O
iSPNs	O
inhibited	O
these	O
responses	O
.	O

In	O
LID	O
mice	O
,	O
hM3Dq	O
stimulation	B:C1148560
of	O
dSPNs	O
exacerbated	O
dyskinetic	O
responses	O
to	O
L	O
-	I:C0023570
DOPA	I:C0023570
,	O
while	O
stimulation	O
of	O
iSPNs	O
inhibited	O
these	O
responses	O
.	O

In	O
LID	O
mice	O
,	O
hM3Dq	O
stimulation	O
of	O
dSPNs	B:C0027882
exacerbated	O
dyskinetic	O
responses	O
to	O
L	O
-	I:C0023570
DOPA	I:C0023570
,	O
while	O
stimulation	O
of	O
iSPNs	O
inhibited	O
these	O
responses	O
.	O

In	O
LID	O
mice	O
,	O
hM3Dq	O
stimulation	O
of	O
dSPNs	O
exacerbated	O
dyskinetic	O
responses	O
to	O
L	B:C0023570
-	I:C0023570
DOPA	I:C0023570
,	O
while	O
stimulation	O
of	O
iSPNs	O
inhibited	O
these	O
responses	O
.	O

In	O
LID	O
mice	O
,	O
hM3Dq	O
stimulation	O
of	O
dSPNs	O
exacerbated	O
dyskinetic	O
responses	O
to	O
L	O
-	I:C0023570
DOPA	I:C0023570
,	O
while	O
stimulation	B:C1148560
of	O
iSPNs	O
inhibited	O
these	O
responses	O
.	O

In	O
LID	O
mice	O
,	O
hM3Dq	O
stimulation	O
of	O
dSPNs	O
exacerbated	O
dyskinetic	O
responses	O
to	O
L	O
-	I:C0023570
DOPA	I:C0023570
,	O
while	O
stimulation	O
of	O
iSPNs	B:C0027882
inhibited	O
these	O
responses	O
.	O

In	O
the	O
absence	O
of	O
L	B:C0023570
-	I:C0023570
DOPA	I:C0023570
,	O
only	O
chemogenetic	O
stimulation	I:C1148560
of	O
dSPNs	O
mediated	O
through	O
the	O
Gs-	O
coupled	I:C0289799
modified	I:C0289799
rat	I:C0289799
muscarinic	I:C0289799
M3	I:C0289799
receptor	I:C0289799
(	O
rM3Ds	O
)	O
induced	O
appreciable	O
dyskinesia	O
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
.	O

In	O
the	O
absence	O
of	O
L	O
-	I:C0023570
DOPA	I:C0023570
,	O
only	O
chemogenetic	B:C1148560
stimulation	I:C1148560
of	O
dSPNs	O
mediated	O
through	O
the	O
Gs-	O
coupled	I:C0289799
modified	I:C0289799
rat	I:C0289799
muscarinic	I:C0289799
M3	I:C0289799
receptor	I:C0289799
(	O
rM3Ds	O
)	O
induced	O
appreciable	O
dyskinesia	O
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
.	O

In	O
the	O
absence	O
of	O
L	O
-	I:C0023570
DOPA	I:C0023570
,	O
only	O
chemogenetic	O
stimulation	I:C1148560
of	O
dSPNs	B:C0027882
mediated	O
through	O
the	O
Gs-	O
coupled	I:C0289799
modified	I:C0289799
rat	I:C0289799
muscarinic	I:C0289799
M3	I:C0289799
receptor	I:C0289799
(	O
rM3Ds	O
)	O
induced	O
appreciable	O
dyskinesia	O
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
.	O

In	O
the	O
absence	O
of	O
L	O
-	I:C0023570
DOPA	I:C0023570
,	O
only	O
chemogenetic	O
stimulation	I:C1148560
of	O
dSPNs	O
mediated	O
through	O
the	O
Gs-	B:C0289799
coupled	I:C0289799
modified	I:C0289799
rat	I:C0289799
muscarinic	I:C0289799
M3	I:C0289799
receptor	I:C0289799
(	O
rM3Ds	O
)	O
induced	O
appreciable	O
dyskinesia	O
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
.	O

In	O
the	O
absence	O
of	O
L	O
-	I:C0023570
DOPA	I:C0023570
,	O
only	O
chemogenetic	O
stimulation	I:C1148560
of	O
dSPNs	O
mediated	O
through	O
the	O
Gs-	O
coupled	I:C0289799
modified	I:C0289799
rat	I:C0289799
muscarinic	I:C0289799
M3	I:C0289799
receptor	I:C0289799
(	O
rM3Ds	B:C0289799
)	O
induced	O
appreciable	O
dyskinesia	O
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
.	O

In	O
the	O
absence	O
of	O
L	O
-	I:C0023570
DOPA	I:C0023570
,	O
only	O
chemogenetic	O
stimulation	I:C1148560
of	O
dSPNs	O
mediated	O
through	O
the	O
Gs-	O
coupled	I:C0289799
modified	I:C0289799
rat	I:C0289799
muscarinic	I:C0289799
M3	I:C0289799
receptor	I:C0289799
(	O
rM3Ds	O
)	O
induced	O
appreciable	O
dyskinesia	B:C0013384
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	O
.	O

In	O
the	O
absence	O
of	O
L	O
-	I:C0023570
DOPA	I:C0023570
,	O
only	O
chemogenetic	O
stimulation	I:C1148560
of	O
dSPNs	O
mediated	O
through	O
the	O
Gs-	O
coupled	I:C0289799
modified	I:C0289799
rat	I:C0289799
muscarinic	I:C0289799
M3	I:C0289799
receptor	I:C0289799
(	O
rM3Ds	O
)	O
induced	O
appreciable	O
dyskinesia	O
in	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
mice	O
.	O

In	O
the	O
absence	O
of	O
L	O
-	I:C0023570
DOPA	I:C0023570
,	O
only	O
chemogenetic	O
stimulation	I:C1148560
of	O
dSPNs	O
mediated	O
through	O
the	O
Gs-	O
coupled	I:C0289799
modified	I:C0289799
rat	I:C0289799
muscarinic	I:C0289799
M3	I:C0289799
receptor	I:C0289799
(	O
rM3Ds	O
)	O
induced	O
appreciable	O
dyskinesia	O
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
mice	B:C0025929
.	O

Combining	O
D2	B:C0058698
receptor	I:C0058698
agonist	O
treatment	O
with	O
rM3Ds	O
-	I:C1148560
dSPN	I:C1148560
stimulation	I:C1148560
reproduced	O
all	O
symptoms	O
of	O
LID	O
.	O

Combining	O
D2	O
receptor	I:C0058698
agonist	B:C2987634
treatment	O
with	O
rM3Ds	O
-	I:C1148560
dSPN	I:C1148560
stimulation	I:C1148560
reproduced	O
all	O
symptoms	O
of	O
LID	O
.	O

Combining	O
D2	O
receptor	I:C0058698
agonist	O
treatment	O
with	O
rM3Ds	B:C1148560
-	I:C1148560
dSPN	I:C1148560
stimulation	I:C1148560
reproduced	O
all	O
symptoms	O
of	O
LID	O
.	O

Combining	O
D2	O
receptor	I:C0058698
agonist	O
treatment	O
with	O
rM3Ds	O
-	I:C1148560
dSPN	I:C1148560
stimulation	I:C1148560
reproduced	O
all	O
symptoms	B:C1457887
of	O
LID	O
.	O

Combining	O
D2	O
receptor	I:C0058698
agonist	O
treatment	O
with	O
rM3Ds	O
-	I:C1148560
dSPN	I:C1148560
stimulation	I:C1148560
reproduced	O
all	O
symptoms	O
of	O
LID	B:C3552620
.	O

These	O
results	O
demonstrate	O
that	O
dSPNs	B:C0027882
and	O
iSPNs	O
oppositely	O
modulate	O
both	O
therapeutic	O
and	O
dyskinetic	O
responses	O
to	O
dopamine	O
replacement	O
therapy	I:C0279033
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
.	O

These	O
results	O
demonstrate	O
that	O
dSPNs	O
and	O
iSPNs	B:C0027882
oppositely	O
modulate	O
both	O
therapeutic	O
and	O
dyskinetic	O
responses	O
to	O
dopamine	O
replacement	O
therapy	I:C0279033
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
.	O

These	O
results	O
demonstrate	O
that	O
dSPNs	O
and	O
iSPNs	O
oppositely	O
modulate	O
both	O
therapeutic	O
and	O
dyskinetic	O
responses	O
to	O
dopamine	B:C0013030
replacement	O
therapy	I:C0279033
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
.	O

These	O
results	O
demonstrate	O
that	O
dSPNs	O
and	O
iSPNs	O
oppositely	O
modulate	O
both	O
therapeutic	O
and	O
dyskinetic	O
responses	O
to	O
dopamine	O
replacement	B:C0279033
therapy	I:C0279033
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
.	O

These	O
results	O
demonstrate	O
that	O
dSPNs	O
and	O
iSPNs	O
oppositely	O
modulate	O
both	O
therapeutic	O
and	O
dyskinetic	O
responses	O
to	O
dopamine	O
replacement	O
therapy	I:C0279033
in	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
.	O

We	O
also	O
show	O
that	O
chemogenetic	B:C1148560
stimulation	I:C1148560
of	O
different	O
signaling	O
pathways	I:C0037080
in	O
dSPNs	O
leads	O
to	O
markedly	O
different	O
motor	O
outcomes	O
.	O

We	O
also	O
show	O
that	O
chemogenetic	O
stimulation	I:C1148560
of	O
different	O
signaling	B:C0037080
pathways	I:C0037080
in	O
dSPNs	O
leads	O
to	O
markedly	O
different	O
motor	O
outcomes	O
.	O

We	O
also	O
show	O
that	O
chemogenetic	O
stimulation	I:C1148560
of	O
different	O
signaling	O
pathways	I:C0037080
in	O
dSPNs	B:C0027882
leads	O
to	O
markedly	O
different	O
motor	O
outcomes	O
.	O

Our	O
findings	O
have	O
important	O
implications	O
for	O
the	O
design	O
of	O
effective	O
antiparkinsonian	B:C0013216
and	I:C0013216
antidyskinetic	I:C0013216
drug	I:C0013216
therapies	I:C0013216
.	O

